Jun Wang
Affiliations: | Pharmaceutical Sciences | State University of New York, Buffalo, Buffalo, NY, United States |
Google:
"Jun Wang"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wang J, Chen T, Ruszaj DM, et al. (2023) Integrated PK/PD modeling relates Smoothened inhibitor biomarkers to the heterogeneous intratumor disposition of cetuximab in pancreatic cancer tumor models. Journal of Pharmaceutical Sciences |
Greene MK, Chen T, Robinson E, et al. (2020) Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer |
Wang J, Chan DK, Sen A, et al. (2019) Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. Molecular Cancer Therapeutics |
Chan D, Minx C, Wang J, et al. (2018) Abstract 3704: Efficacy of DR5-targeted immunoliposomes in pancreatic cancer models primed with SMO inhibitors Cancer Research. 78: 3704-3704 |
Wang J, Qu Y, Pitoniak R, et al. (2014) Abstract 2691: Smo-targeted sonic hedgehog signaling inhibitor enhances therapeutic antibody deposition and efficacy in a patient-derived pancreatic ductal adenocarcinoma model Cancer Research. 74: 2691-2691 |